Abstract:Background Concurrent non-alcoholic fatty liver disease (NAFLD) is common in patients with chronic HBV infection. But the impact of fatty liver on the histologic progression of HBV infection remains controversial. Methods Consecutive HBV-infected patients who underwent liver biopsy between 2016 and 2021 were included. Alcohol consumption and other types of viral hepatitis were excluded. All biopsies were scored for grading and staging by Scheuer’s score, and the steatosis was scored as an estimate of the percentage of liver parenchyma replaced by fat. Logistic regression analyses were applied to assess the associated factors for significant liver inflammation (G ≥ 2), significant fibrosis (S ≥ 2) and advanced fibrosis (S ≥ 3). Results Among the 871 HBV-infected patients, hepatic steatosis was prevalent in 255 patients (29.28%). Significant liver inflammation was present in 461 patients (52.93%). Significant fibrosis was observed in 527 patients (60.51%), while advanced liver fibrosis was observed in 171 patients (19.63%). Patients with concomitant NAFLD were more likely to have significant liver inflammation and advanced fibrosis. Fatty liver was an independent risk factor for significant liver inflammation (OR: 2.117, 95% CI: 1.500-2.988), but it could not predict the development of fibrosis. Especially, in HBV-infected patients with persistent normal ALT (immune tolerant and inactive carrier phase), the presence of significant liver inflammation was higher in NAFLD than those without NAFLD. The prevalence of advanced liver fibrosis was higher in NAFLD than non-NAFLD only in the immune tolerant phase, while NAFLD did not increase fibrosis burden in other stages of HBV infection. We developed a predictive model for significant liver inflammation with the area under receiver operating characteristic curve (AUROC) of 0.825, and a model for significant fibrosis with the AUROC of 0.760. Conclusions NAFLD is independently associated with significant liver inflammation, and increases the burden of advanced liver fibrosis in HBV-infected patients. The influence of NAFLD on the degree of liver inflammation and fibrosis is different in distinct clinical phases of chronic HBV infection.

[Characteristics, Diagnostic and Therapeutic Strategies for Chronic Hepatitis B Combined with Non-Alcoholic Fatty Liver Disease].

Characteristics, Diagnosis and Management of Concomitant Fatty Liver in Hepatitis B Patients

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

Natural History and Non-Invasive Diagnosis and Clinical Management of Chronic HBV Infection Overlapping with Non-Alcoholic Fatty Liver Disease

Clinical Impact and Mechanisms of Hepatitis B Virus Infection Concurrent with Non-Alcoholic Fatty Liver Disease

Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection

Hepatitis B Virus Infection Combined with Nonalcoholic Fatty Liver Disease: Interaction and Prognosis

Chronic Hepatitis B and Non‐alcoholic Fatty Liver Disease: Conspirators or Competitors?

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients

Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review

Clinical Research Advances in Chronic Hepatitis B Complicated by Fatty Liver Disease

Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: a Systematic Review and Meta-Analysis

Interaction Between Hepatitis B Virus Replication and Lipid Metabolism in Patients with Chronic Hepatitis B and NAFLD

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic Hepatitis B

The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Diagnosis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Disease

How to evaluate combination therapy using interferon and nucleos(t)ide analogues